175206-66-3

Upstream product

• 133332-49-7 (3-cyclopentyloxy-4-methoxyphenyl)methanol 
• 67387-76-2 3-cyclopentyloxy-4-methoxybenzylaldehyde 

Downstream Products

• 141332-75-4 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine 
• 183660-31-3 1-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclopropanecarbonitrile 
• 183660-33-5 C-[1-(3-cyclopentyloxy-4-methoxy-phenyl)-cyclopropyl]-methylamine 
• 225100-00-5 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurine]-2-yl-3-oxypropyl]pyridine N-oxide 
• 225099-81-0 9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethyl-2-[3-(4-pyridyl)propyloxy]purine 
• 141333-36-0 4-cyanomethyl-2-cyclopentyloxy-1-methoxybenzene 
• 225100-12-9 2-chloro-9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurine 
• 847978-31-8 4-{1-[6-amino-3-(3-cyclopentyloxy-4-methoxy-benzyl)-3H-purin-8-yl]-1-methyl-ethoxymethyl}-benzoic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.

This communication describes the synthesis and in vitro PDE4 inhibitory activity of a novel series of imidazol-2-one and 2-cyanoiminoimidazole derivatives. The compounds described were also tested in in vivo models to evaluate their anti-inflammatory activity after topical administration as well as their gastro-intestinal side effects. Several compounds proved to be potent PDE4 inhibitors and some 2-cyanoiminoimidazoles showed less pronounced gastro-intestinal side effects than reference compounds but maintained anti-inflammatory activity after topical administration.

Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids

This invention relates to a method of preparing a compound of the following type by treating a compound of formula (II) with lithium bromide, magnesium bromide and the like.

METHOD FOR PREPARING SUBSTITUTED 4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS

This invention relates to a method of preparing a compound type where at least one of R′ or R″ is a carboxyl group (I) by treating a compound of formula (II) with a Group I(a) or Group II(a) metal halide, with an aprotic dipolar amide-based solvent and wa

Phenylpyridyl compounds for inhibiting phosphodiesterase IV and methods of using same

PCT No. PCT/US96/00519 Sec. 371 Date Nov. 13, 1997 Sec. 102(e) Date Nov. 13, 1997 PCT Filed Jan. 11, 1996 PCT Pub. No. WO96/21435 PCT Pub. Date Jul. 18, 1996Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improve

Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV

Rolipram-based PDE IV inhibitors containing phenyl- or benzyl-substituted moieties of the formula: STR1 wherein X1 and X2 may be the same or different and each is O or S; R1 is selected from the group consisting of hydroge